Akorn, Inc.

This committee provides official revenue estimates and technical analysis for all tax legislation. Its work directly shapes corporate tax structures, capital investment credits, and the overall tax burden, significantly impacting Akorn's financial performance.

This committee controls taxation, trade, and entitlement spending (Medicare/Medicaid). Tax policy directly impacts corporate profitability, and Medicare/Medicaid pricing policies are critical determinants of revenue and market access for prescription drugs.

This committee allocates discretionary federal spending. Its subcommittees determine precise funding for health-related agencies (e.g., FDA, NIH) and government purchases (e.g., VA pharmaceuticals), directly affecting the operating environment and potential revenue streams for pharmaceutical companies.

This committee directly regulates the FDA, which is critical for drug approval, safety, and labeling—the core of Akorn's business. Its influence on NIH funding also shapes the broader pharmaceutical research landscape.

This committee oversees antitrust laws and intellectual property. Patent protection is fundamental to pharmaceutical companies, and antitrust oversight directly impacts potential mergers, acquisitions, and market competition within the industry.